KALBE LAUNCHED KALGEN INNOLAB CLINICAL LABORATORY

Jakarta, 18 January 2018 - PT Kalbe FarmaTbk (Kalbe) through its subsidiary PT Innolab Sains Internasional (PT ISI) today launched Kalgen Innolab Clinical Laboratory, as a new venture engaging in laboratory services offering basic up to advanced tests such as molecular diagnostics to support personalized medicine. Kalgen Innolab Clinical Laboratory is the first foreign joint investment in clinical laboratories between Indonesia and Japan, and has obtained the approval of Ministry of Health of Republic of Indonesia in line with the Minister of Health Regulation Number 411/MENKES/PER/III/2010 regarding Clinical Laboratory. PT Innolab Sains Internasional is a joint venture company of PT Kalbio Global Medika (Kalbe's subsidiary), Health Science Research Institute, Inc. (HSRI), or 'Hoken Kagaku Kenkyujo (HKK)' in Japanese, and Toyota Tsusho Corporation (TTC).

Escalating health problems and diseases have created an increasing demand for effective treatment, where timely and accurate diagnosis is vital. Diagnostic checkups play an essential role in responding to these needs. Unfortunately, many checkups have to be performed offshore due to limited domestic resources and competence, resulting in a longer Turn Around Time. Further, increasing diagnostic requirements have not been accompanied by a standardized quality level among laboratories.

The launch of the Jaminan Kesehatan Nasional (JKN), or National Health Insurance in 2014 has brought significant impact to access and demand for health care services in Indonesia. This has called for improvements in the availability and quality of health facilities, medicines, as well as diagnostic services that must be accompanied by improved efficiency at all aspects.

'Through partnership with these reputable foreign partners, we hope to ensure a high standard laboratory services on par with Japanese standard and to gain access and leverage on their existing networking,' stated Vidjongtius, President Director of PT Kalbe FarmaTbk, 'We will perform bench marking process and technology transfer to improve the quality of laboratory services.'

Kalgen Innolab Clinical Laboratory will adopt HSRI's and TTC's systems, with strong emphasis on Quality, Completeness, Faster Turn Around Time and Competitive Price. Thus, Kalgen Innolab Clinical Laboratory will offer a broad test portfolio, an international standard quality management system, an integrated Laboratory Information Systems (LIS) as well as the technology transfer of sophisticated test such as Cytogenetics. Responding to the challenges in the era of universal insurance coverage, partnership with hospitals can be formed to help hospitals manage the laboratories more efficiently with proper quality standards.

The Laboratory Information Systems (LIS) of Kalgen Innolab is developed by adopting the LIS of HSRI Clinical Laboratories chains all around Japan with a proven track record in managing approximately 2,500,000 sample ID per month, starting from sample receipt, testing, to reporting, where a manual process would be exposed to potential errors.The LIS of Kalgen Innolab feature certain advantages such as no requirement for high bandwidth connection, automatic periodical data backup,flexibility of storage media (Hard disk Tape), and solid data security system due to its independence from third-party applications.

Both HSRI and TTC consider Indonesia to be a highly attractive market, in particular for health care. Large population base and shifting disease pattern from infectious to lifestyle diseases have together created a growing demand for more diverse and higher quality clinical testing. Being the leading player in pharmaceutical market with well established access to health care facilities and extensive networking, Kalbe is very well positioned to meaningfully contribute to this partnership. This strong market access and networking, combined with the latest know-how in laboratory testing supported by robust information and management system, are expected to provide a solid leverage to successfully penetrate the laboratory testing market. Through this collaboration, we aim to be the leading clinical laboratory testing center and ultimately contribute to create access to better health care for Indonesia.

About Innolab Sains Internasional
Innolab Sains International (ISI) is the first Indonesia - Japan joint venture on Clinical Laboratory. ISI aspires to be the best reference Clinical Laboratory in Indonesia by :
• Offering the highest quality of comprehensive and responsive laboratory services leveraging on cutting-edge technology, enabled by excellent management system
• Becoming the partner of choice in the trend of personalized medicine and wellness
ISI is committed to deliver the highest level of service quality, professionalism and best-practice clinical care with patients' well being as the utmost priority.

About Health Science Research Institute, Inc Jepang (HSRI)
Health Sciences Research Institute Inc. (HSRI), or 'Hoken Kagaku Kenkyujo' (HKK) in Japanese, was established in 1950 as the first commercial clinical testing center in Japan. The company'smission is 'accurate data, swift report'.HSRI has beencontributingto people's health forover 68 years with reliable service networks of 93 sales offices and 52 laboratories, and covers the wide range of tests which include Biochemistry, Hematology, Microbiology, Genetics, Oncology, and Pathology, which reach around 4,000 test parameters in total. The company has identified some key strategies -to apply new testing technologies into business, to enter into overseas markets, and to develop human resources.
For more information about HSRI, visit the Company's website at www.hkk.co.jp

About Toyota Tsusho Corporation (TTC)
Toyota Tsusho Corporation (TTC) was founded in 1948 as the trading company for the Toyota Group. Today, Toyota Tsusho operates in more than 120 countries with approximately 58,000 Group employees, all striving to contribute to the creation of prosperous societies. Toyota Tsusho continues to expand as a global leader in vehicle exports and automobile production support. The company has seven operating divisions (Metals/ Global Parts & Logistics/ Automotive/ Machinery, Energy & Project/ Chemicals & Electronics/ Food & Consumer Services/ Africa) focused on around three business fields.These are the Mobility field, which contributes to future convenient societies, the Resources & Environment field, which ensures sustainable societies, and the Life & Community field, which supports comfortable and healthy lifestyles.
For more information about TTC, visit the Company's website at www.toyota-tsusho.com

About Kalbe
PT Kalbe Farma Tbk. ('Kalbe') was established in 1966 and is one of the largest publicly-listed pharmaceutical companies in Southeast Asia. Kalbe has four main divisions managing a broad and strong portfolio of brands; prescription pharmaceuticals division (Cefspan, Brainact, Broadced, etc), consumer health division comprising over-the-counter drugs (Promag, Mixagrip, Komix, Woods, Fatigon, etc) as well as ready-to-drink and energy drink products (Hydro Coco, Extra Joss), nutritionals division (ChilKid, Prenagen, Diabetasol, etc), and distribution division. Kalbe currently has more than 30 subsidiaries and 10 production facilities with international standards, supported by around 17,000 employees spread in 72 branches across Indonesia. Since 1991, Kalbe's shares have been listed on the Indonesia Stock Exchange (IDX: KLBF).
For more information about Kalbe, visit the Company's website at www.kalbe.co.id

--oOo--